TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06687941: A Multi-center, Open-label, Dose Escalation and Expansion, Phase 1 Study to Evaluate the Tolerability, Safety and Pharmacokinetics of AST-201 in Patients With GPC3-positive Advanced Solid Tumors

Sponsor: Aptamer Sciences, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 70 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,607,984

Rescue Site Savings

+$5,686,296

Unlock Full NCT06687941 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06687941 Rescue Dossier →